Oncology in The Precision Medicine Era

by Claudio Carini (Editor), Mark Fidock (Editor), van Gool, Alain (Editor)
Handbook of Biomarkers and Precision Medicine provides comprehensive insights into biomarker discovery and development which has driven the new era of Precision Medicine

This volume is dedicated to Artificial intelligence (AI). It is taking on an increasingly important role in our society today. This book discusses and examines AI applications in medicine and biology as well as challenges and opportunities in this fascinating area.

This book, authors discusses the development of techniques in machine learning for improving the efficiency of oncology drug development and delivering cost-effective precision treatment. Authors consider how to structure data for drug repurposing and target identification, how to improve clinical trials and how patients may view artificial intelligence.

This book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma. In the era of precision medicine, numerous new anticancer agents, such as molecular targeted agents and immune checkpoint inhibitors, have been developed to improve outcomes in cancer patients. FDG PET plays a key role in evaluating the effects of these novel treatments because it can detect changes in the metabolic activity of tumors before any reduction in their size is visible on other imaging modalities. Accordingly, FDG PET is of prognostic as well as diagnostic value, and allows prompt changes in patient management.